T1	Participants 365 461	95 subjects enrolled in the United States Food and Drug Administration Phase III clinical trials
T2	Participants 740 800	96% of subjects (86 of 90) having less than 1.00 D of change
T3	Participants 482 547	99% of patients (89 of 90) had 20/40 uncorrected vision or better
